CHMMF (Chimeric Therapeutics) Other Current Liabilities: $0.59 Mil (As of Dec. 2025)


CHMMF Chimeric Therapeutics Ltd CHMMF
13 GF Score
Price $0.10
! 1 Warning Sign
View Full Analysis

What is Chimeric Therapeutics Other Current Liabilities?

Chimeric Therapeutics CHMMF -96.67% 13 Other Current Liabilities is $0.59 Mil as of Dec. 2025. GuruFocus rates CHMMF with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Chimeric Therapeutics's other current liabilities for the quarter that ended in Dec. 2025 was $0.59 Mil.

Chimeric Therapeutics's quarterly other current liabilities increased from Dec. 2024 ($1.85 Mil) to Jun. 2025 ($2.44 Mil) but then declined from Jun. 2025 ($2.44 Mil) to Dec. 2025 ($0.59 Mil).

Chimeric Therapeutics's annual other current liabilities increased from Jun. 2023 ($2.40 Mil) to Jun. 2024 ($2.59 Mil) but then declined from Jun. 2024 ($2.59 Mil) to Jun. 2025 ($2.44 Mil).

Chimeric Therapeutics Other Current Liabilities Related Terms

Chimeric Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Chimeric Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chimeric Therapeutics Other Current Liabilities Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Liabilities
3.30 1.86 2.40 2.59 2.44

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.33 2.59 1.85 2.44 0.59
CHMMF
13GF Score
Chimeric Therapeutics Ltd CHMMF
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chimeric Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.59 Mil mean?
Chimeric Therapeutics (CHMMF) has a Other Current Liabilities of $0.59 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Chimeric Therapeutics.
Is Chimeric Therapeutics' Other Current Liabilities too high?
Chimeric Therapeutics' current Other Current Liabilities is $0.59 Mil. Overall, Chimeric Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Chimeric Therapeutics' Other Current Liabilities compare to VRTX and REGN?
Chimeric Therapeutics' Other Current Liabilities of $0.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Chimeric Therapeutics. Chimeric Therapeutics's current Other Current Liabilities is $0.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (CHMMF) has a current Other Current Liabilities of $0.59 Mil. The current Other Current Liabilities is $0.59 Mil. Chimeric Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Chimeric Therapeutics (CHMMF), the current Other Current Liabilities is $0.59 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chimeric Therapeutics Business Description

Other Exchanges CHM:Australia
Address 62 Lygon Street, Level 3, Carlton, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
13GF Score

Get the complete analysis for CHMMF

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price